189 related articles for article (PubMed ID: 18237272)
1. Ubiquitin-mediated proteasomal degradation of non-synonymous SNP variants of human ABC transporter ABCG2.
Nakagawa H; Tamura A; Wakabayashi K; Hoshijima K; Komada M; Yoshida T; Kometani S; Matsubara T; Mikuriya K; Ishikawa T
Biochem J; 2008 May; 411(3):623-31. PubMed ID: 18237272
[TBL] [Abstract][Full Text] [Related]
2. Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations.
Furukawa T; Wakabayashi K; Tamura A; Nakagawa H; Morishima Y; Osawa Y; Ishikawa T
Pharm Res; 2009 Feb; 26(2):469-79. PubMed ID: 18958403
[TBL] [Abstract][Full Text] [Related]
3. Disruption of N-linked glycosylation enhances ubiquitin-mediated proteasomal degradation of the human ATP-binding cassette transporter ABCG2.
Nakagawa H; Wakabayashi-Nakao K; Tamura A; Toyoda Y; Koshiba S; Ishikawa T
FEBS J; 2009 Dec; 276(24):7237-52. PubMed ID: 19909340
[TBL] [Abstract][Full Text] [Related]
4. Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2.
Tamura A; Wakabayashi K; Onishi Y; Takeda M; Ikegami Y; Sawada S; Tsuji M; Matsuda Y; Ishikawa T
Cancer Sci; 2007 Feb; 98(2):231-9. PubMed ID: 17297656
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphisms of human ABC transporter ABCG2: development of the standard method for functional validation of SNPs by using the Flp recombinase system.
Tamura A; Wakabayashi K; Onishi Y; Nakagawa H; Tsuji M; Matsuda Y; Ishikawa T
J Exp Ther Oncol; 2006; 6(1):1-11. PubMed ID: 17228519
[TBL] [Abstract][Full Text] [Related]
6. Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transport.
Tamura A; Watanabe M; Saito H; Nakagawa H; Kamachi T; Okura I; Ishikawa T
Mol Pharmacol; 2006 Jul; 70(1):287-96. PubMed ID: 16608919
[TBL] [Abstract][Full Text] [Related]
7. Intramolecular disulfide bond is a critical check point determining degradative fates of ATP-binding cassette (ABC) transporter ABCG2 protein.
Wakabayashi K; Nakagawa H; Tamura A; Koshiba S; Hoshijima K; Komada M; Ishikawa T
J Biol Chem; 2007 Sep; 282(38):27841-6. PubMed ID: 17686774
[TBL] [Abstract][Full Text] [Related]
8. Quality control of human ABCG2 protein in the endoplasmic reticulum: ubiquitination and proteasomal degradation.
Wakabayashi-Nakao K; Tamura A; Furukawa T; Nakagawa H; Ishikawa T
Adv Drug Deliv Rev; 2009 Jan; 61(1):66-72. PubMed ID: 19111842
[TBL] [Abstract][Full Text] [Related]
9. In vitro evaluation of photosensitivity risk related to genetic polymorphisms of human ABC transporter ABCG2 and inhibition by drugs.
Tamura A; Onishi Y; An R; Koshiba S; Wakabayashi K; Hoshijima K; Priebe W; Yoshida T; Kometani S; Matsubara T; Mikuriya K; Ishikawa T
Drug Metab Pharmacokinet; 2007 Dec; 22(6):428-40. PubMed ID: 18159130
[TBL] [Abstract][Full Text] [Related]
10. The C421A (Q141K) polymorphism enhances the 3'-untranslated region (3'-UTR)-dependent regulation of ATP-binding cassette transporter ABCG2.
Ripperger A; Benndorf RA
Biochem Pharmacol; 2016 Mar; 104():139-47. PubMed ID: 26903388
[TBL] [Abstract][Full Text] [Related]
11. Methods to examine the impact of nonsynonymous SNPs on protein degradation and function of human ABC transporter.
Ishikawa T; Wakabayashi-Nakao K; Nakagawa H
Methods Mol Biol; 2013; 1015():225-50. PubMed ID: 23824860
[TBL] [Abstract][Full Text] [Related]
12. Effect of Walker A mutation (K86M) on oligomerization and surface targeting of the multidrug resistance transporter ABCG2.
Henriksen U; Gether U; Litman T
J Cell Sci; 2005 Apr; 118(Pt 7):1417-26. PubMed ID: 15769853
[TBL] [Abstract][Full Text] [Related]
13. Functional analysis of SNPs variants of BCRP/ABCG2.
Kondo C; Suzuki H; Itoda M; Ozawa S; Sawada J; Kobayashi D; Ieiri I; Mine K; Ohtsubo K; Sugiyama Y
Pharm Res; 2004 Oct; 21(10):1895-903. PubMed ID: 15553238
[TBL] [Abstract][Full Text] [Related]
14. N-Linked glycosylation of the human ABC transporter ABCG2 on asparagine 596 is not essential for expression, transport activity, or trafficking to the plasma membrane.
Diop NK; Hrycyna CA
Biochemistry; 2005 Apr; 44(14):5420-9. PubMed ID: 15807535
[TBL] [Abstract][Full Text] [Related]
15. Impact of genetic variability in the ABCG2 gene on ABCG2 expression, function, and interaction with AT1 receptor antagonist telmisartan.
Deppe S; Ripperger A; Weiss J; Ergün S; Benndorf RA
Biochem Biophys Res Commun; 2014 Jan; 443(4):1211-7. PubMed ID: 24388985
[TBL] [Abstract][Full Text] [Related]
16. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2.
Mizuarai S; Aozasa N; Kotani H
Int J Cancer; 2004 Mar; 109(2):238-46. PubMed ID: 14750175
[TBL] [Abstract][Full Text] [Related]
17. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
18. Identification of cysteine residues critically involved in homodimer formation and protein expression of human ATP-binding cassette transporter ABCG2: a new approach using the flp recombinase system.
Wakabayashi K; Nakagawa H; Adachi T; Kii I; Kobatake E; Kudo A; Ishikawa T
J Exp Ther Oncol; 2006; 5(3):205-22. PubMed ID: 16528971
[TBL] [Abstract][Full Text] [Related]
19. Low molecular weight heparin ablates lung cancer cisplatin-resistance by inducing proteasome-mediated ABCG2 protein degradation.
Niu Q; Wang W; Li Y; Ruden DM; Wang F; Li Y; Wang F; Song J; Zheng K
PLoS One; 2012; 7(7):e41035. PubMed ID: 22844424
[TBL] [Abstract][Full Text] [Related]
20. Human ABC transporter ABCG2 in cancer chemotherapy and pharmacogenomics.
Ishikawa T; Nakagawa H
J Exp Ther Oncol; 2009; 8(1):5-24. PubMed ID: 19827267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
